nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—glaucoma	0.5	1	CbGaD
Lenalidomide—TNFSF11—Differentiation Pathway—CNTF—glaucoma	0.0212	0.242	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—NTF4—glaucoma	0.0112	0.127	CbGpPWpGaD
Lenalidomide—CDH5—endothelium—glaucoma	0.00742	0.368	CbGeAlD
Lenalidomide—TNFSF11—connective tissue—glaucoma	0.00466	0.231	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—NCK2—glaucoma	0.00437	0.0498	CbGpPWpGaD
Lenalidomide—CDH5—connective tissue—glaucoma	0.00351	0.174	CbGeAlD
Lenalidomide—Pomalidomide—TNF—glaucoma	0.00324	0.412	CrCbGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—CAV1—glaucoma	0.00314	0.0358	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NCK2—glaucoma	0.00304	0.0346	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NCK2—glaucoma	0.00287	0.0327	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—BCL2L1—glaucoma	0.00284	0.0324	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—NCK2—glaucoma	0.0026	0.0296	CbGpPWpGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—NOS3—glaucoma	0.00237	0.027	CbGpPWpGaD
Lenalidomide—CRBN—retina—glaucoma	0.00229	0.114	CbGeAlD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—ANXA3—glaucoma	0.00219	0.025	CbGpPWpGaD
Lenalidomide—Thalidomide—TNF—glaucoma	0.00208	0.266	CrCbGaD
Lenalidomide—ABCB1—ABC-family proteins mediated transport—PEX19—glaucoma	0.00165	0.0188	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—CAV1—glaucoma	0.00154	0.0176	CbGpPWpGaD
Lenalidomide—Pomalidomide—PTGS2—glaucoma	0.00154	0.196	CrCbGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PTGFR—glaucoma	0.0015	0.017	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—glaucoma	0.00147	0.0167	CbGpPWpGaD
Lenalidomide—PTGS2—endothelium—glaucoma	0.00128	0.0637	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—glaucoma	0.00117	0.0133	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CAV1—glaucoma	0.00107	0.0122	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—CAV1—glaucoma	0.00101	0.0116	CbGpPWpGaD
Lenalidomide—Thalidomide—PTGS2—glaucoma	0.00099	0.126	CrCbGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—glaucoma	0.000841	0.00958	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NOS3—glaucoma	0.000812	0.00925	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NOS3—glaucoma	0.000767	0.00874	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—glaucoma	0.000691	0.00788	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CA1—glaucoma	0.000678	0.00772	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LRP12—glaucoma	0.000628	0.00716	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000612	0.00697	CbGpPWpGaD
Lenalidomide—PTGS2—connective tissue—glaucoma	0.000607	0.0301	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—glaucoma	0.000585	0.00667	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—glaucoma	0.000552	0.00629	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—FN1—glaucoma	0.00055	0.00626	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.000497	0.00567	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—glaucoma	0.000437	0.00498	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—OPN4—glaucoma	0.000436	0.00496	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000434	0.00494	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TXN—glaucoma	0.000421	0.0048	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000409	0.00466	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HEYL—glaucoma	0.000405	0.00461	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000394	0.00449	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTGFR—glaucoma	0.000392	0.00447	CbGpPWpGaD
Lenalidomide—ABCB1—retina—glaucoma	0.000386	0.0192	CbGeAlD
Lenalidomide—PTGS2—Spinal Cord Injury—C1QB—glaucoma	0.000373	0.00425	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—glaucoma	0.000361	0.00411	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—glaucoma	0.000315	0.00358	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RPTOR—glaucoma	0.000307	0.0035	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NCK2—glaucoma	0.000297	0.00339	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—glaucoma	0.00027	0.00307	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ABCA1—glaucoma	0.00026	0.00296	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HDAC9—glaucoma	0.000253	0.00288	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD1—glaucoma	0.000232	0.00264	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—GSTM1—glaucoma	0.000216	0.00246	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—NGFR—glaucoma	0.000198	0.00226	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SMO—glaucoma	0.000198	0.00225	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—EDN1—glaucoma	0.000188	0.00214	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	0.000186	0.00212	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—glaucoma	0.000185	0.00211	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—glaucoma	0.000184	0.00209	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NTRK2—glaucoma	0.000181	0.00206	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—BDNF—glaucoma	0.000172	0.00196	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PEX19—glaucoma	0.000172	0.00196	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000172	0.00196	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1A—glaucoma	0.000165	0.00188	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL1A—glaucoma	0.000162	0.00184	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NGFR—glaucoma	0.000155	0.00177	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	0.000155	0.00177	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NTRK1—glaucoma	0.000147	0.00168	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—glaucoma	0.000146	0.00166	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FAS—glaucoma	0.000144	0.00164	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000142	0.00162	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—C3—glaucoma	0.000142	0.00162	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN2B—glaucoma	0.000136	0.00155	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CA5A—glaucoma	0.000134	0.00152	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NARFL—glaucoma	0.000134	0.00152	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—glaucoma	0.000133	0.00151	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EDN1—glaucoma	0.00013	0.00149	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—glaucoma	0.00013	0.00148	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000128	0.00146	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Clonidine—glaucoma	0.000127	0.000331	CcSEcCtD
Lenalidomide—Feeling abnormal—Brinzolamide—glaucoma	0.000127	0.00033	CcSEcCtD
Lenalidomide—Mental disorder—Betaxolol—glaucoma	0.000127	0.00033	CcSEcCtD
Lenalidomide—Pain—Pilocarpine—glaucoma	0.000126	0.000329	CcSEcCtD
Lenalidomide—Constipation—Pilocarpine—glaucoma	0.000126	0.000329	CcSEcCtD
Lenalidomide—Cough—Clonidine—glaucoma	0.000126	0.000328	CcSEcCtD
Lenalidomide—Sweating—Timolol—glaucoma	0.000126	0.000328	CcSEcCtD
Lenalidomide—Dizziness—Apraclonidine—glaucoma	0.000126	0.000328	CcSEcCtD
Lenalidomide—Erythema—Betaxolol—glaucoma	0.000126	0.000327	CcSEcCtD
Lenalidomide—Malnutrition—Betaxolol—glaucoma	0.000126	0.000327	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—glaucoma	0.000126	0.00143	CbGpPWpGaD
Lenalidomide—Urticaria—Dorzolamide—glaucoma	0.000124	0.000323	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—glaucoma	0.000124	0.00142	CbGpPWpGaD
Lenalidomide—Epistaxis—Timolol—glaucoma	0.000124	0.000323	CcSEcCtD
Lenalidomide—Abdominal pain—Dorzolamide—glaucoma	0.000124	0.000322	CcSEcCtD
Lenalidomide—Body temperature increased—Dorzolamide—glaucoma	0.000124	0.000322	CcSEcCtD
Lenalidomide—Tension—Betaxolol—glaucoma	0.000124	0.000321	CcSEcCtD
Lenalidomide—Sinusitis—Timolol—glaucoma	0.000124	0.000321	CcSEcCtD
Lenalidomide—Dysgeusia—Betaxolol—glaucoma	0.000123	0.000321	CcSEcCtD
Lenalidomide—Chest pain—Clonidine—glaucoma	0.000123	0.00032	CcSEcCtD
Lenalidomide—Arthralgia—Clonidine—glaucoma	0.000123	0.00032	CcSEcCtD
Lenalidomide—Abdominal pain—Travoprost—glaucoma	0.000123	0.00032	CcSEcCtD
Lenalidomide—Agranulocytosis—Timolol—glaucoma	0.000123	0.000319	CcSEcCtD
Lenalidomide—Anxiety—Clonidine—glaucoma	0.000123	0.000319	CcSEcCtD
Lenalidomide—Asthenia—Acetazolamide—glaucoma	0.000123	0.000318	CcSEcCtD
Lenalidomide—Dizziness—Bimatoprost—glaucoma	0.000122	0.000318	CcSEcCtD
Lenalidomide—Nervousness—Betaxolol—glaucoma	0.000122	0.000318	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000122	0.000318	CcSEcCtD
Lenalidomide—Urticaria—Brinzolamide—glaucoma	0.000122	0.000318	CcSEcCtD
Lenalidomide—Feeling abnormal—Pilocarpine—glaucoma	0.000122	0.000317	CcSEcCtD
Lenalidomide—Discomfort—Clonidine—glaucoma	0.000122	0.000316	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000122	0.00139	CbGpPWpGaD
Lenalidomide—Vomiting—Apraclonidine—glaucoma	0.000121	0.000316	CcSEcCtD
Lenalidomide—Muscle spasms—Betaxolol—glaucoma	0.000121	0.000315	CcSEcCtD
Lenalidomide—PTGS2—Disease—LRP12—glaucoma	0.000121	0.00138	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Pilocarpine—glaucoma	0.000121	0.000314	CcSEcCtD
Lenalidomide—Hypersensitivity—Brimonidine—glaucoma	0.000121	0.000314	CcSEcCtD
Lenalidomide—Dry mouth—Clonidine—glaucoma	0.00012	0.000313	CcSEcCtD
Lenalidomide—Bradycardia—Timolol—glaucoma	0.00012	0.000313	CcSEcCtD
Lenalidomide—Dermatitis—Apraclonidine—glaucoma	0.00012	0.000313	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NGF—glaucoma	0.00012	0.00137	CbGpPWpGaD
Lenalidomide—Headache—Apraclonidine—glaucoma	0.00012	0.000311	CcSEcCtD
Lenalidomide—Confusional state—Clonidine—glaucoma	0.000119	0.00031	CcSEcCtD
Lenalidomide—Vision blurred—Betaxolol—glaucoma	0.000119	0.000309	CcSEcCtD
Lenalidomide—Rhinitis—Timolol—glaucoma	0.000119	0.000308	CcSEcCtD
Lenalidomide—Oedema—Clonidine—glaucoma	0.000118	0.000307	CcSEcCtD
Lenalidomide—Tremor—Betaxolol—glaucoma	0.000118	0.000307	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000118	0.00134	CbGpPWpGaD
Lenalidomide—Hallucination—Timolol—glaucoma	0.000118	0.000306	CcSEcCtD
Lenalidomide—Asthenia—Brimonidine—glaucoma	0.000118	0.000306	CcSEcCtD
Lenalidomide—Infection—Clonidine—glaucoma	0.000117	0.000305	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000117	0.00133	CbGpPWpGaD
Lenalidomide—Body temperature increased—Pilocarpine—glaucoma	0.000117	0.000304	CcSEcCtD
Lenalidomide—Abdominal pain—Pilocarpine—glaucoma	0.000117	0.000304	CcSEcCtD
Lenalidomide—Ill-defined disorder—Betaxolol—glaucoma	0.000117	0.000304	CcSEcCtD
Lenalidomide—Diarrhoea—Acetazolamide—glaucoma	0.000117	0.000304	CcSEcCtD
Lenalidomide—Rash—Bimatoprost—glaucoma	0.000117	0.000303	CcSEcCtD
Lenalidomide—Dermatitis—Bimatoprost—glaucoma	0.000117	0.000303	CcSEcCtD
Lenalidomide—Oedema peripheral—Timolol—glaucoma	0.000116	0.000303	CcSEcCtD
Lenalidomide—Anaemia—Betaxolol—glaucoma	0.000116	0.000303	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000116	0.00133	CbGpPWpGaD
Lenalidomide—Shock—Clonidine—glaucoma	0.000116	0.000302	CcSEcCtD
Lenalidomide—Connective tissue disorder—Timolol—glaucoma	0.000116	0.000302	CcSEcCtD
Lenalidomide—Pruritus—Brimonidine—glaucoma	0.000116	0.000301	CcSEcCtD
Lenalidomide—Headache—Bimatoprost—glaucoma	0.000116	0.000301	CcSEcCtD
Lenalidomide—Nervous system disorder—Clonidine—glaucoma	0.000116	0.000301	CcSEcCtD
Lenalidomide—Thrombocytopenia—Clonidine—glaucoma	0.000116	0.000301	CcSEcCtD
Lenalidomide—Hypersensitivity—Dorzolamide—glaucoma	0.000115	0.0003	CcSEcCtD
Lenalidomide—Tachycardia—Clonidine—glaucoma	0.000115	0.0003	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—glaucoma	0.000115	0.00131	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Travoprost—glaucoma	0.000115	0.000298	CcSEcCtD
Lenalidomide—Skin disorder—Clonidine—glaucoma	0.000115	0.000298	CcSEcCtD
Lenalidomide—Hyperhidrosis—Clonidine—glaucoma	0.000114	0.000297	CcSEcCtD
Lenalidomide—Visual impairment—Timolol—glaucoma	0.000114	0.000296	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—C3—glaucoma	0.000114	0.0013	CbGpPWpGaD
Lenalidomide—Malaise—Betaxolol—glaucoma	0.000114	0.000295	CcSEcCtD
Lenalidomide—Nausea—Apraclonidine—glaucoma	0.000113	0.000295	CcSEcCtD
Lenalidomide—Hypersensitivity—Brinzolamide—glaucoma	0.000113	0.000295	CcSEcCtD
Lenalidomide—Vertigo—Betaxolol—glaucoma	0.000113	0.000294	CcSEcCtD
Lenalidomide—Syncope—Betaxolol—glaucoma	0.000113	0.000294	CcSEcCtD
Lenalidomide—Dizziness—Acetazolamide—glaucoma	0.000113	0.000294	CcSEcCtD
Lenalidomide—Anorexia—Clonidine—glaucoma	0.000113	0.000293	CcSEcCtD
Lenalidomide—Asthenia—Dorzolamide—glaucoma	0.000112	0.000292	CcSEcCtD
Lenalidomide—Asthenia—Travoprost—glaucoma	0.000112	0.000291	CcSEcCtD
Lenalidomide—Palpitations—Betaxolol—glaucoma	0.000111	0.000289	CcSEcCtD
Lenalidomide—Pruritus—Dorzolamide—glaucoma	0.000111	0.000288	CcSEcCtD
Lenalidomide—Loss of consciousness—Betaxolol—glaucoma	0.000111	0.000288	CcSEcCtD
Lenalidomide—Eye disorder—Timolol—glaucoma	0.00011	0.000287	CcSEcCtD
Lenalidomide—Asthenia—Brinzolamide—glaucoma	0.00011	0.000287	CcSEcCtD
Lenalidomide—Hypotension—Clonidine—glaucoma	0.00011	0.000287	CcSEcCtD
Lenalidomide—Pruritus—Travoprost—glaucoma	0.00011	0.000287	CcSEcCtD
Lenalidomide—Tinnitus—Timolol—glaucoma	0.00011	0.000287	CcSEcCtD
Lenalidomide—Cough—Betaxolol—glaucoma	0.00011	0.000286	CcSEcCtD
Lenalidomide—Nausea—Bimatoprost—glaucoma	0.00011	0.000286	CcSEcCtD
Lenalidomide—Cardiac disorder—Timolol—glaucoma	0.00011	0.000285	CcSEcCtD
Lenalidomide—Hypersensitivity—Pilocarpine—glaucoma	0.000109	0.000283	CcSEcCtD
Lenalidomide—Pruritus—Brinzolamide—glaucoma	0.000109	0.000283	CcSEcCtD
Lenalidomide—Vomiting—Acetazolamide—glaucoma	0.000109	0.000282	CcSEcCtD
Lenalidomide—Dizziness—Brimonidine—glaucoma	0.000108	0.000282	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Clonidine—glaucoma	0.000108	0.00028	CcSEcCtD
Lenalidomide—Angiopathy—Timolol—glaucoma	0.000107	0.000279	CcSEcCtD
Lenalidomide—Arthralgia—Betaxolol—glaucoma	0.000107	0.000279	CcSEcCtD
Lenalidomide—Chest pain—Betaxolol—glaucoma	0.000107	0.000279	CcSEcCtD
Lenalidomide—Myalgia—Betaxolol—glaucoma	0.000107	0.000279	CcSEcCtD
Lenalidomide—Diarrhoea—Dorzolamide—glaucoma	0.000107	0.000278	CcSEcCtD
Lenalidomide—Headache—Acetazolamide—glaucoma	0.000107	0.000278	CcSEcCtD
Lenalidomide—Anxiety—Betaxolol—glaucoma	0.000107	0.000278	CcSEcCtD
Lenalidomide—Insomnia—Clonidine—glaucoma	0.000107	0.000278	CcSEcCtD
Lenalidomide—Immune system disorder—Timolol—glaucoma	0.000107	0.000278	CcSEcCtD
Lenalidomide—Diarrhoea—Travoprost—glaucoma	0.000107	0.000277	CcSEcCtD
Lenalidomide—Mediastinal disorder—Timolol—glaucoma	0.000107	0.000277	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000107	0.000277	CcSEcCtD
Lenalidomide—Asthenia—Pilocarpine—glaucoma	0.000106	0.000276	CcSEcCtD
Lenalidomide—Paraesthesia—Clonidine—glaucoma	0.000106	0.000276	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—APOE—glaucoma	0.000106	0.00121	CbGpPWpGaD
Lenalidomide—Discomfort—Betaxolol—glaucoma	0.000106	0.000275	CcSEcCtD
Lenalidomide—Arrhythmia—Timolol—glaucoma	0.000106	0.000275	CcSEcCtD
Lenalidomide—Dyspnoea—Clonidine—glaucoma	0.000105	0.000274	CcSEcCtD
Lenalidomide—Diarrhoea—Brinzolamide—glaucoma	0.000105	0.000274	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CAV1—glaucoma	0.000105	0.0012	CbGpPWpGaD
Lenalidomide—Somnolence—Clonidine—glaucoma	0.000105	0.000273	CcSEcCtD
Lenalidomide—Dry mouth—Betaxolol—glaucoma	0.000105	0.000273	CcSEcCtD
Lenalidomide—Pruritus—Pilocarpine—glaucoma	0.000105	0.000272	CcSEcCtD
Lenalidomide—Alopecia—Timolol—glaucoma	0.000104	0.000272	CcSEcCtD
Lenalidomide—Confusional state—Betaxolol—glaucoma	0.000104	0.00027	CcSEcCtD
Lenalidomide—Mental disorder—Timolol—glaucoma	0.000104	0.000269	CcSEcCtD
Lenalidomide—Dizziness—Dorzolamide—glaucoma	0.000103	0.000269	CcSEcCtD
Lenalidomide—Rash—Brimonidine—glaucoma	0.000103	0.000269	CcSEcCtD
Lenalidomide—Dermatitis—Brimonidine—glaucoma	0.000103	0.000268	CcSEcCtD
Lenalidomide—Dizziness—Travoprost—glaucoma	0.000103	0.000268	CcSEcCtD
Lenalidomide—Malnutrition—Timolol—glaucoma	0.000103	0.000268	CcSEcCtD
Lenalidomide—Erythema—Timolol—glaucoma	0.000103	0.000268	CcSEcCtD
Lenalidomide—Oedema—Betaxolol—glaucoma	0.000103	0.000267	CcSEcCtD
Lenalidomide—Headache—Brimonidine—glaucoma	0.000103	0.000267	CcSEcCtD
Lenalidomide—Decreased appetite—Clonidine—glaucoma	0.000103	0.000267	CcSEcCtD
Lenalidomide—Infection—Betaxolol—glaucoma	0.000102	0.000266	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Clonidine—glaucoma	0.000102	0.000265	CcSEcCtD
Lenalidomide—Fatigue—Clonidine—glaucoma	0.000102	0.000265	CcSEcCtD
Lenalidomide—Dizziness—Brinzolamide—glaucoma	0.000102	0.000265	CcSEcCtD
Lenalidomide—Nausea—Acetazolamide—glaucoma	0.000101	0.000264	CcSEcCtD
Lenalidomide—Diarrhoea—Pilocarpine—glaucoma	0.000101	0.000263	CcSEcCtD
Lenalidomide—Shock—Betaxolol—glaucoma	0.000101	0.000263	CcSEcCtD
Lenalidomide—Tension—Timolol—glaucoma	0.000101	0.000263	CcSEcCtD
Lenalidomide—Constipation—Clonidine—glaucoma	0.000101	0.000263	CcSEcCtD
Lenalidomide—Pain—Clonidine—glaucoma	0.000101	0.000263	CcSEcCtD
Lenalidomide—Nervous system disorder—Betaxolol—glaucoma	0.000101	0.000262	CcSEcCtD
Lenalidomide—Dysgeusia—Timolol—glaucoma	0.000101	0.000262	CcSEcCtD
Lenalidomide—Thrombocytopenia—Betaxolol—glaucoma	0.000101	0.000262	CcSEcCtD
Lenalidomide—Tachycardia—Betaxolol—glaucoma	0.0001	0.000261	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.0001	0.00114	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FN1—glaucoma	0.0001	0.00114	CbGpPWpGaD
Lenalidomide—Nervousness—Timolol—glaucoma	0.0001	0.00026	CcSEcCtD
Lenalidomide—Skin disorder—Betaxolol—glaucoma	9.99e-05	0.00026	CcSEcCtD
Lenalidomide—Vomiting—Dorzolamide—glaucoma	9.95e-05	0.000259	CcSEcCtD
Lenalidomide—Hyperhidrosis—Betaxolol—glaucoma	9.94e-05	0.000258	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—BAD—glaucoma	9.88e-05	0.00113	CbGpPWpGaD
Lenalidomide—Rash—Dorzolamide—glaucoma	9.87e-05	0.000257	CcSEcCtD
Lenalidomide—Dermatitis—Dorzolamide—glaucoma	9.86e-05	0.000256	CcSEcCtD
Lenalidomide—Rash—Travoprost—glaucoma	9.83e-05	0.000255	CcSEcCtD
Lenalidomide—Dermatitis—Travoprost—glaucoma	9.82e-05	0.000255	CcSEcCtD
Lenalidomide—Headache—Dorzolamide—glaucoma	9.81e-05	0.000255	CcSEcCtD
Lenalidomide—Anorexia—Betaxolol—glaucoma	9.8e-05	0.000255	CcSEcCtD
Lenalidomide—Vomiting—Brinzolamide—glaucoma	9.78e-05	0.000254	CcSEcCtD
Lenalidomide—Dizziness—Pilocarpine—glaucoma	9.78e-05	0.000254	CcSEcCtD
Lenalidomide—Headache—Travoprost—glaucoma	9.76e-05	0.000254	CcSEcCtD
Lenalidomide—Nausea—Brimonidine—glaucoma	9.73e-05	0.000253	CcSEcCtD
Lenalidomide—Feeling abnormal—Clonidine—glaucoma	9.73e-05	0.000253	CcSEcCtD
Lenalidomide—Rash—Brinzolamide—glaucoma	9.7e-05	0.000252	CcSEcCtD
Lenalidomide—Vision blurred—Timolol—glaucoma	9.7e-05	0.000252	CcSEcCtD
Lenalidomide—Dermatitis—Brinzolamide—glaucoma	9.69e-05	0.000252	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Clonidine—glaucoma	9.66e-05	0.000251	CcSEcCtD
Lenalidomide—Headache—Brinzolamide—glaucoma	9.64e-05	0.000251	CcSEcCtD
Lenalidomide—Hypotension—Betaxolol—glaucoma	9.61e-05	0.00025	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—NARFL—glaucoma	9.48e-05	0.00108	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA5A—glaucoma	9.48e-05	0.00108	CbGpPWpGaD
Lenalidomide—Angioedema—Timolol—glaucoma	9.4e-05	0.000244	CcSEcCtD
Lenalidomide—Vomiting—Pilocarpine—glaucoma	9.4e-05	0.000244	CcSEcCtD
Lenalidomide—Urticaria—Clonidine—glaucoma	9.38e-05	0.000244	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Betaxolol—glaucoma	9.37e-05	0.000244	CcSEcCtD
Lenalidomide—Abdominal pain—Clonidine—glaucoma	9.34e-05	0.000243	CcSEcCtD
Lenalidomide—Body temperature increased—Clonidine—glaucoma	9.34e-05	0.000243	CcSEcCtD
Lenalidomide—Rash—Pilocarpine—glaucoma	9.32e-05	0.000242	CcSEcCtD
Lenalidomide—Dermatitis—Pilocarpine—glaucoma	9.32e-05	0.000242	CcSEcCtD
Lenalidomide—Insomnia—Betaxolol—glaucoma	9.3e-05	0.000242	CcSEcCtD
Lenalidomide—Nausea—Dorzolamide—glaucoma	9.3e-05	0.000242	CcSEcCtD
Lenalidomide—Headache—Pilocarpine—glaucoma	9.26e-05	0.000241	CcSEcCtD
Lenalidomide—Nausea—Travoprost—glaucoma	9.26e-05	0.000241	CcSEcCtD
Lenalidomide—Vertigo—Timolol—glaucoma	9.25e-05	0.00024	CcSEcCtD
Lenalidomide—Paraesthesia—Betaxolol—glaucoma	9.23e-05	0.00024	CcSEcCtD
Lenalidomide—Syncope—Timolol—glaucoma	9.23e-05	0.00024	CcSEcCtD
Lenalidomide—Dyspnoea—Betaxolol—glaucoma	9.17e-05	0.000238	CcSEcCtD
Lenalidomide—Nausea—Brinzolamide—glaucoma	9.14e-05	0.000238	CcSEcCtD
Lenalidomide—Palpitations—Timolol—glaucoma	9.1e-05	0.000236	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	9.07e-05	0.00103	CbGpPWpGaD
Lenalidomide—Dyspepsia—Betaxolol—glaucoma	9.05e-05	0.000235	CcSEcCtD
Lenalidomide—Loss of consciousness—Timolol—glaucoma	9.05e-05	0.000235	CcSEcCtD
Lenalidomide—Cough—Timolol—glaucoma	8.98e-05	0.000233	CcSEcCtD
Lenalidomide—Decreased appetite—Betaxolol—glaucoma	8.94e-05	0.000232	CcSEcCtD
Lenalidomide—Hypertension—Timolol—glaucoma	8.89e-05	0.000231	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Betaxolol—glaucoma	8.88e-05	0.000231	CcSEcCtD
Lenalidomide—Fatigue—Betaxolol—glaucoma	8.86e-05	0.00023	CcSEcCtD
Lenalidomide—Constipation—Betaxolol—glaucoma	8.79e-05	0.000229	CcSEcCtD
Lenalidomide—Pain—Betaxolol—glaucoma	8.79e-05	0.000229	CcSEcCtD
Lenalidomide—Nausea—Pilocarpine—glaucoma	8.78e-05	0.000228	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CDKN1B—glaucoma	8.78e-05	0.001	CbGpPWpGaD
Lenalidomide—Myalgia—Timolol—glaucoma	8.76e-05	0.000228	CcSEcCtD
Lenalidomide—Chest pain—Timolol—glaucoma	8.76e-05	0.000228	CcSEcCtD
Lenalidomide—Arthralgia—Timolol—glaucoma	8.76e-05	0.000228	CcSEcCtD
Lenalidomide—Anxiety—Timolol—glaucoma	8.73e-05	0.000227	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	8.7e-05	0.000226	CcSEcCtD
Lenalidomide—Hypersensitivity—Clonidine—glaucoma	8.7e-05	0.000226	CcSEcCtD
Lenalidomide—Discomfort—Timolol—glaucoma	8.66e-05	0.000225	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	8.57e-05	0.000977	CbGpPWpGaD
Lenalidomide—Dry mouth—Timolol—glaucoma	8.57e-05	0.000223	CcSEcCtD
Lenalidomide—Asthenia—Clonidine—glaucoma	8.47e-05	0.00022	CcSEcCtD
Lenalidomide—Feeling abnormal—Betaxolol—glaucoma	8.47e-05	0.00022	CcSEcCtD
Lenalidomide—Confusional state—Timolol—glaucoma	8.47e-05	0.00022	CcSEcCtD
Lenalidomide—Oedema—Timolol—glaucoma	8.4e-05	0.000218	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	8.36e-05	0.000952	CbGpPWpGaD
Lenalidomide—Pruritus—Clonidine—glaucoma	8.36e-05	0.000217	CcSEcCtD
Lenalidomide—Infection—Timolol—glaucoma	8.35e-05	0.000217	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	8.3e-05	0.000946	CbGpPWpGaD
Lenalidomide—Shock—Timolol—glaucoma	8.26e-05	0.000215	CcSEcCtD
Lenalidomide—Nervous system disorder—Timolol—glaucoma	8.24e-05	0.000214	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	8.24e-05	0.000938	CbGpPWpGaD
Lenalidomide—Urticaria—Betaxolol—glaucoma	8.17e-05	0.000212	CcSEcCtD
Lenalidomide—Skin disorder—Timolol—glaucoma	8.16e-05	0.000212	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—glaucoma	8.13e-05	0.000926	CbGpPWpGaD
Lenalidomide—Body temperature increased—Betaxolol—glaucoma	8.13e-05	0.000211	CcSEcCtD
Lenalidomide—Hyperhidrosis—Timolol—glaucoma	8.12e-05	0.000211	CcSEcCtD
Lenalidomide—Diarrhoea—Clonidine—glaucoma	8.08e-05	0.00021	CcSEcCtD
Lenalidomide—Anorexia—Timolol—glaucoma	8.01e-05	0.000208	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NOS3—glaucoma	7.94e-05	0.000905	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—glaucoma	7.91e-05	0.000901	CbGpPWpGaD
Lenalidomide—Hypotension—Timolol—glaucoma	7.85e-05	0.000204	CcSEcCtD
Lenalidomide—Dizziness—Clonidine—glaucoma	7.81e-05	0.000203	CcSEcCtD
Lenalidomide—PTGS2—Disease—HEYL—glaucoma	7.8e-05	0.000889	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR1OP—glaucoma	7.8e-05	0.000889	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	7.76e-05	0.000884	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Timolol—glaucoma	7.65e-05	0.000199	CcSEcCtD
Lenalidomide—Insomnia—Timolol—glaucoma	7.6e-05	0.000197	CcSEcCtD
Lenalidomide—Hypersensitivity—Betaxolol—glaucoma	7.58e-05	0.000197	CcSEcCtD
Lenalidomide—Paraesthesia—Timolol—glaucoma	7.54e-05	0.000196	CcSEcCtD
Lenalidomide—Vomiting—Clonidine—glaucoma	7.51e-05	0.000195	CcSEcCtD
Lenalidomide—Dyspnoea—Timolol—glaucoma	7.49e-05	0.000195	CcSEcCtD
Lenalidomide—Somnolence—Timolol—glaucoma	7.47e-05	0.000194	CcSEcCtD
Lenalidomide—Rash—Clonidine—glaucoma	7.45e-05	0.000194	CcSEcCtD
Lenalidomide—Dermatitis—Clonidine—glaucoma	7.44e-05	0.000193	CcSEcCtD
Lenalidomide—Headache—Clonidine—glaucoma	7.4e-05	0.000192	CcSEcCtD
Lenalidomide—Dyspepsia—Timolol—glaucoma	7.39e-05	0.000192	CcSEcCtD
Lenalidomide—Asthenia—Betaxolol—glaucoma	7.38e-05	0.000192	CcSEcCtD
Lenalidomide—Decreased appetite—Timolol—glaucoma	7.3e-05	0.00019	CcSEcCtD
Lenalidomide—Pruritus—Betaxolol—glaucoma	7.27e-05	0.000189	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Timolol—glaucoma	7.25e-05	0.000189	CcSEcCtD
Lenalidomide—Fatigue—Timolol—glaucoma	7.24e-05	0.000188	CcSEcCtD
Lenalidomide—Pain—Timolol—glaucoma	7.18e-05	0.000187	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—glaucoma	7.13e-05	0.000813	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	7.11e-05	0.00081	CbGpPWpGaD
Lenalidomide—Diarrhoea—Betaxolol—glaucoma	7.04e-05	0.000183	CcSEcCtD
Lenalidomide—Nausea—Clonidine—glaucoma	7.02e-05	0.000182	CcSEcCtD
Lenalidomide—Feeling abnormal—Timolol—glaucoma	6.92e-05	0.00018	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CDKN1B—glaucoma	6.88e-05	0.000784	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Timolol—glaucoma	6.87e-05	0.000179	CcSEcCtD
Lenalidomide—Dizziness—Betaxolol—glaucoma	6.8e-05	0.000177	CcSEcCtD
Lenalidomide—Urticaria—Timolol—glaucoma	6.67e-05	0.000173	CcSEcCtD
Lenalidomide—Body temperature increased—Timolol—glaucoma	6.64e-05	0.000173	CcSEcCtD
Lenalidomide—Abdominal pain—Timolol—glaucoma	6.64e-05	0.000173	CcSEcCtD
Lenalidomide—Vomiting—Betaxolol—glaucoma	6.54e-05	0.00017	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—CA1—glaucoma	6.53e-05	0.000744	CbGpPWpGaD
Lenalidomide—Rash—Betaxolol—glaucoma	6.48e-05	0.000169	CcSEcCtD
Lenalidomide—Dermatitis—Betaxolol—glaucoma	6.48e-05	0.000168	CcSEcCtD
Lenalidomide—Headache—Betaxolol—glaucoma	6.44e-05	0.000167	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MMP9—glaucoma	6.37e-05	0.000726	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CTSA—glaucoma	6.33e-05	0.000721	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—glaucoma	6.26e-05	0.000713	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Timolol—glaucoma	6.19e-05	0.000161	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TNF—glaucoma	6.11e-05	0.000697	CbGpPWpGaD
Lenalidomide—Nausea—Betaxolol—glaucoma	6.11e-05	0.000159	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	6.08e-05	0.000692	CbGpPWpGaD
Lenalidomide—Asthenia—Timolol—glaucoma	6.03e-05	0.000157	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—CA2—glaucoma	5.98e-05	0.000681	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	5.97e-05	0.00068	CbGpPWpGaD
Lenalidomide—Pruritus—Timolol—glaucoma	5.94e-05	0.000154	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	5.84e-05	0.000666	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	5.84e-05	0.000666	CbGpPWpGaD
Lenalidomide—Diarrhoea—Timolol—glaucoma	5.75e-05	0.000149	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—glaucoma	5.72e-05	0.000652	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	5.68e-05	0.000647	CbGpPWpGaD
Lenalidomide—Dizziness—Timolol—glaucoma	5.55e-05	0.000144	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—glaucoma	5.52e-05	0.000628	CbGpPWpGaD
Lenalidomide—Vomiting—Timolol—glaucoma	5.34e-05	0.000139	CcSEcCtD
Lenalidomide—Rash—Timolol—glaucoma	5.3e-05	0.000138	CcSEcCtD
Lenalidomide—Dermatitis—Timolol—glaucoma	5.29e-05	0.000138	CcSEcCtD
Lenalidomide—Headache—Timolol—glaucoma	5.26e-05	0.000137	CcSEcCtD
Lenalidomide—Nausea—Timolol—glaucoma	4.99e-05	0.00013	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	4.97e-05	0.000566	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HDAC9—glaucoma	4.87e-05	0.000555	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA1—glaucoma	4.63e-05	0.000528	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CTSA—glaucoma	4.49e-05	0.000511	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	4.47e-05	0.000509	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—glaucoma	4.32e-05	0.000493	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	4.26e-05	0.000485	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA2—glaucoma	4.24e-05	0.000483	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	4.23e-05	0.000482	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TXN—glaucoma	4.21e-05	0.00048	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—glaucoma	3.84e-05	0.000438	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	3.81e-05	0.000434	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	3.75e-05	0.000428	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	3.52e-05	0.000401	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTT1—glaucoma	3.26e-05	0.000372	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	3.02e-05	0.000344	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TXN—glaucoma	2.98e-05	0.00034	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	2.66e-05	0.000303	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN2B—glaucoma	2.62e-05	0.000298	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCA1—glaucoma	2.6e-05	0.000296	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1B1—glaucoma	2.6e-05	0.000296	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—glaucoma	2.31e-05	0.000264	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—glaucoma	2.19e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—glaucoma	2.08e-05	0.000237	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOE—glaucoma	2.04e-05	0.000233	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CAV1—glaucoma	2.02e-05	0.000231	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BAD—glaucoma	1.9e-05	0.000217	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1B1—glaucoma	1.84e-05	0.00021	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCA1—glaucoma	1.84e-05	0.00021	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—glaucoma	1.84e-05	0.000209	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOE—glaucoma	1.71e-05	0.000195	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAV1—glaucoma	1.7e-05	0.000193	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—glaucoma	1.53e-05	0.000174	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—glaucoma	1.47e-05	0.000168	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1B—glaucoma	1.33e-05	0.000151	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—glaucoma	1.3e-05	0.000148	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—glaucoma	1.28e-05	0.000146	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOE—glaucoma	1.21e-05	0.000138	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAV1—glaucoma	1.2e-05	0.000137	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—glaucoma	9.09e-06	0.000104	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—glaucoma	8.31e-06	9.47e-05	CbGpPWpGaD
